Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Updated
https://www.withpower.com/trial/phase-1-sarcoma-6-2021-6f477
Risks are now minimal IMHO Vs Rewards could be huge lol ..... Any day a huge RNS could be delivered and if your out then you will find it very difficult to get in !! Results next week .... AVA3996 / AVA6000 Updated ...Next news before results ? Something will drop before next week IMHO come on Sir Al
If you’re developing world beating new therapeutics, then its crucial doctors, key opinion leaders and healthcare professionals fully understand the drug's benefits, utility and safety profile.
In this context,
Avacta
(
AVCT
)
Follow
is currently showcasing its second major pre|CISION based treatment - a novel proteasome inhibitor (AVA3996) - at the 2023 American Association for Cancer Research annual conference in Florida. One of the world’s premiere such events.
What's more, this commitment suggests to me the company is excited about AVA3996's long-term potential, and ticking off another important milestone along the road to fully commercialising the wider pre|CISION platform.
The AVA3993 pre-clinical data being presented demonstrates;
1) The release of the active proteasome inhibitor (AVA2727D) from AVA3996 is specific to the enzyme FAP, which is upregulated in most solid tumours.
2) In a head to head study, AVA2727D kills cancers cells (ex-vivo) as effectively as bortezomib (Takeda's Velcade), which is one of the approved proteasome inhibitors on the estimated $2.3bn annual market by 2026.
3) In 3 different in-vivo (mouse) cancer models (melanoma, sarcoma and colorectal cancer), AVA3996 was as effective as other related chemotherapies.
4) The significant toxicities associated with bortezomib observed in these in-vivo models were not observed in the case of AVA3996. Suggesting that the exposure to the raw drug had been reduced due to the tumour targeting of the pre|CISION chemistry in AVA3996.
CEO Alastair Smith commented: "We are delighted with the progress being made in the pre-clinical development of AVA3996, the 2nd drug candidate based on our preICISIONTM platform. The potential to apply a proteasome inhibitor to the treatment of solid tumours is very exciting. And, as can be seen from our poster presented at the prestigious AACR meeting, the pre-clinical data we are generating is very encouraging in that regard. We are focused on accelerating AVA3996 through to IND filing as soon as possible, so that it can follow AVA6000 into the clinic next year."
https://www.voxmarkets.co.uk/articles/avacta-reveals-more-development-progress-for-precision-treatments-0c4b990
Preliminary results are scheduled for Tuesday 25th April.
Mr Tap today ......
https://www.medscape.org/viewarticle/867872
Don't Forget Affyxell 12th April ......
Jong Sang Ryu, Ph.D., CEO and Chief Security Officer
April 12 | 10:45am | Dark Horse Consulting Ballroom
Gimhae, South Korea
(Private)
AffyXell Therapeutics is a joint venture between Daewoong Pharmaceutical and Avacta Group, developing a novel cell and gene therapy to tackle diseases that come from the imbalance of immune system homeostasis. AffyXell’s platform (also known as AFX) was created by converging two proprietary technologies of its parent companies – Daewoong’s mesenchymal stem cell (MSC) and Avacta’s Affimer® platform. The immunomodulation function by MSC is further increased with the Affimer®, and the treatment developed by the AFX platform enhances restoring immunologic balance. AffyXell is developing pipelines taking this new therapeutic approach to lead in resolving fundamental causes of intractable diseases like immune rejection and autoimmune diseases
Presenting 12th Apr & Big Reveal in May
https://meetingonthemed.com
https://www.isctglobal.org/isct2023/program/2023plenaryandconcurrents
Must admit haven't seen this before clearly we are not letting go AVA6000
Key Objectives 2023-2025
Complete the phase I clinical study for AVA6000 FAP-activated doxorubicin.
Leverage the AVA6000 clinical data to commercialise the broader preCISIONTM platform through licensing whilst retaining AVA6000 as a wholly owned asset.
Expand the number of fully funded partnerships and licensing deals for the Affimer® therapeutic platform.
Demonstrate safety and tolerability of the Affimer® platform by progressing the first Affimer® into the clinic as quickly as possible with partners and through in-house programmes.
Grow the Diagnostics Division through M&A to build a profitable European IVD business serving both healthcare professionals and consumers.
https://www.abstractsonline.com/pp8/#!/10828/presentation/2606
We have demonstrated that the pre|CISION™ substrate is exquisitely sensitive to FAP and is not cleaved by related proteases. The active AVA3996 warhead should therefore be released primarily following FAP cleavage in the tumor microenvironment.
Cancer cell lines were assessed for their sensitivity to AVA3996 in vitro: activity was typically 100-fold less than the active warhead or Bortezomib alone. Upon co-incubation with soluble FAP, potency of AVA3996 increased to similar levels as seen for the warhead alone demonstrating the masking effect of the pre|CISION™ substrate. A DRF/MTD study established the maximum tolerated dose in rats was around 6-fold higher for AVA3996 compared to warhead alone. This provides further evidence that AVA3996 can be dosed at higher levels than proteasome inhibitor alone, with the potential for greater tumor targeting and hence reduced systemic toxicity.
Ongoing in vivo and co-culture studies aim to further validate the efficacy and tolerability profile of AVA3996 to direct future development of this drug. In addition, the data supports wider utility of the pre|CISION™ platform to target therapeutics to the tumor while reducing systemic dose-limiting toxicities
https://www.abstractsonline.com/pp8/#!/10828/presentation/2606
We have demonstrated that the pre|CISION™ substrate is exquisitely sensitive to FAP and is not cleaved by related proteases. The active AVA3996 warhead should therefore be released primarily following FAP cleavage in the tumor microenvironment.
Cancer cell lines were assessed for their sensitivity to AVA3996 in vitro: activity was typically 100-fold less than the active warhead or Bortezomib alone. Upon co-incubation with soluble FAP, potency of AVA3996 increased to similar levels as seen for the warhead alone demonstrating the masking effect of the pre|CISION™ substrate. A DRF/MTD study established the maximum tolerated dose in rats was around 6-fold higher for AVA3996 compared to warhead alone. This provides further evidence that AVA3996 can be dosed at higher levels than proteasome inhibitor alone, with the potential for greater tumor targeting and hence reduced systemic toxicity.
Ongoing in vivo and co-culture studies aim to further validate the efficacy and tolerability profile of AVA3996 to direct future development of this drug. In addition, the data supports wider utility of the pre|CISION™ platform to target therapeutics to the tumor while reducing systemic dose-limiting toxicities.
I 100% believe GMCC he is genuine !
We should be discussing why Cohort 5 has not started ?
1) Waiting on dosing levels ( doubt this as it shouldn't take 8 plus weeks )
2) In talks with a Major Player and they have asked for a pause ( Knowing how good current results are ? )
3) FDA Fast track imminent .... doubt this would have stopped us continuing ?
Please feel free to Add / Discus
Perhaps we will get a taster in readiness for the Big reveal in May ?
https://meetingonthemed.com/company-presentations/?n=affyxell-therapeutics